ES2087158T3 - Conjugados de proteinas antiviricas de la hierba carmin y anticuerpos monoclonales. - Google Patents

Conjugados de proteinas antiviricas de la hierba carmin y anticuerpos monoclonales.

Info

Publication number
ES2087158T3
ES2087158T3 ES90911551T ES90911551T ES2087158T3 ES 2087158 T3 ES2087158 T3 ES 2087158T3 ES 90911551 T ES90911551 T ES 90911551T ES 90911551 T ES90911551 T ES 90911551T ES 2087158 T3 ES2087158 T3 ES 2087158T3
Authority
ES
Spain
Prior art keywords
carmin
conjugates
grass
monoclonal antibodies
viral proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911551T
Other languages
English (en)
Inventor
Fatih M Uckun
Joyce Mintzer Zarling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
University of Minnesota
Original Assignee
Oncogen LP
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP, University of Minnesota filed Critical Oncogen LP
Application granted granted Critical
Publication of ES2087158T3 publication Critical patent/ES2087158T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE SUMINISTRAN UNA PROTEINA ANTIVIRAL FITOLACADA (PAP) Y CONJUGADOS ANTICUERPO MONOCLONAL CAPACES DE INHIBIR LA REPRODUCCION DE VIRUS EN CELULA DE MAMIFEROS SIN PRESENTAR FITOTOXICIDAD DETECTABLE.
ES90911551T 1989-07-25 1990-07-12 Conjugados de proteinas antiviricas de la hierba carmin y anticuerpos monoclonales. Expired - Lifetime ES2087158T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30

Publications (1)

Publication Number Publication Date
ES2087158T3 true ES2087158T3 (es) 1996-07-16

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911551T Expired - Lifetime ES2087158T3 (es) 1989-07-25 1990-07-12 Conjugados de proteinas antiviricas de la hierba carmin y anticuerpos monoclonales.

Country Status (17)

Country Link
EP (1) EP0441917B1 (es)
JP (1) JP3109678B2 (es)
KR (1) KR920700698A (es)
AT (1) ATE137410T1 (es)
AU (1) AU631674B2 (es)
CA (1) CA2037900C (es)
DE (1) DE69026812T2 (es)
DK (1) DK0441917T3 (es)
ES (1) ES2087158T3 (es)
FI (1) FI911447A0 (es)
GR (1) GR1002180B (es)
IE (1) IE74143B1 (es)
IL (1) IL95134A (es)
NO (1) NO911174L (es)
NZ (1) NZ234607A (es)
PT (1) PT94789B (es)
WO (1) WO1991001145A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (es) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체

Also Published As

Publication number Publication date
DK0441917T3 (da) 1996-09-16
PT94789A (pt) 1991-03-20
IL95134A (en) 1996-01-31
IE74143B1 (en) 1997-07-02
EP0441917A1 (en) 1991-08-21
DE69026812T2 (de) 1996-11-28
NO911174D0 (no) 1991-03-22
FI911447A0 (fi) 1991-03-25
NZ234607A (en) 1992-10-28
WO1991001145A1 (en) 1991-02-07
CA2037900C (en) 1999-11-16
NO911174L (no) 1991-05-24
PT94789B (pt) 1997-04-30
GR1002180B (en) 1996-03-11
AU631674B2 (en) 1992-12-03
AU6140590A (en) 1991-02-22
CA2037900A1 (en) 1991-01-26
DE69026812D1 (de) 1996-06-05
IL95134A0 (en) 1991-06-10
IE902593A1 (en) 1991-02-27
GR900100550A (el) 1991-12-10
JPH04502625A (ja) 1992-05-14
ATE137410T1 (de) 1996-05-15
KR920700698A (ko) 1992-08-10
JP3109678B2 (ja) 2000-11-20
EP0441917B1 (en) 1996-05-01

Similar Documents

Publication Publication Date Title
DE3585087D1 (de) Retrovirale polypeptide in zusammenhang mit menschlicher transformation.
NO934542L (no) Hepatitt C virus (HCV) polypeptider
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
NO963168D0 (no) Immunstimulatoriske monoklonale antistoffer
SE7900662L (sv) Forfarande och reagens for immunoanalys
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
DK282987D0 (da) Lagdelt immunoanalyseorgan til bestemmelse af et antigens tilstedevaerelse, og hvori der anvendes antistoffer beregnet til transport af partikler
ES2087158T3 (es) Conjugados de proteinas antiviricas de la hierba carmin y anticuerpos monoclonales.
ATE164838T1 (de) Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate
ES2150443T3 (es) Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados.
FR2637897B1 (fr) Dosages immunologiques de l'azt, derives et conjugues et anticorps
ATE196767T1 (de) Neue cocain-derivate und protein- und polypeptid- cocain-derivate, konjugate und markierte verbindungen
DK0442372T3 (da) Forbedrede mærkede haptener, fremgangsmåde til deres fremstilling samt anvendelse af disse mærkede haptener ved immunoassays
DK314886A (da) Histamin-derivat og -immunogen-konjugat, cellelinie og antistof produceret deraf samt immunbestemmelse af histamin ved hjaelp af antistoffet
KR100310413B1 (ko) 인간의자연형lgM항체
ITRM920603A1 (it) La sequenza dell'inserto cprl3, parte del gene della proteina della oociste di cryptosporidium (cowp), e derivati utili per la diagnosi dell'infezione da cryptosporidium
ATE358727T1 (de) Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren
BR0204599A (pt) Sequências de proteìna de núcleo de hcv
GR890100219A (el) Ανθρωπινα μονοκλωνικα αντισωματα που ειδικα αναγνωριζουν κυτταραιου λυσσας κυτταρα που παραγουν τα ιδια, διαμορφωσεις που περιε χουν τα ιδια και παραγωγη ολων αυτων.
DK0638174T3 (da) Detektion af mæslingevirusspecifikke antistoffer under anvendelse af rekombinante mæslingeproteiner
KR860008779A (ko) 항체 형성 화합물의 제조방법
FR2681600B1 (fr) Antigenes specifiquement reconnus par des anticorps specifiques de la polyarthrite rhumatouide, leurs proteines constitutives, leur preparation et leurs applications.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0441917

Country of ref document: ES